Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011, Article ID 751513, 12 pages
http://dx.doi.org/10.4061/2011/751513
Research Article

TRC120038, a Novel Dual AT1/ETA Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats

Torrent Research Centre, Torrent Pharmaceuticals Ltd., Gujarat, Gandhinagar 382428, India

Received 16 June 2011; Revised 26 August 2011; Accepted 20 September 2011

Academic Editor: Thomas Unger

Copyright © 2011 Anookh Mohanan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. V. L. Roger, A. S. Go, D. M. Lloyd-Jones et al., “Heart disease and stroke statistics—2011 update: a report from the American Heart Association,” Circulation, vol. 123, no. 4, pp. e18–e209, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. S. D. Persell, “Prevalence of resistant hypertension in the United States, 2003–2008,” Hypertension, vol. 57, no. 6, pp. 1076–1080, 2011. View at Publisher · View at Google Scholar · View at PubMed
  4. B. J. Epstein, “Efficacy and safety of darusentan: a novel endothelin receptor antagonist,” Annals of Pharmacotherapy, vol. 42, no. 7-8, pp. 1060–1069, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. A. Rodgers, S. MacMahon, T. Yee, and T. Clark, “Blood pressure, cholesterol, and stroke in eastern Asia,” Lancet, vol. 352, no. 9143, pp. 1801–1807, 1998. View at Google Scholar
  6. C. Arauz-Pacheo, M. A. Parrott, and P. Raskin, “Treatment of hypertension in adults with diabetes,” Diabetes Care, vol. 26, no. 1, pp. S80–S82, 2003. View at Google Scholar · View at Scopus
  7. National Kidney Foundation Guideline, “K/DOQI clinical practice guidelines for chronic kidney disease: kidney disease outcome quality initiative,” American Journal of Kidney Diseases, vol. 39, pp. S1–S246, 2002. View at Google Scholar
  8. S. Ergul, D. C. Parish, D. Puett, and A. Ergul, “Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension,” Hypertension, vol. 28, no. 4, pp. 652–655, 1996. View at Google Scholar · View at Scopus
  9. J. H. Laragh, D. B. Case, A. Atlas, and J. E. Sealey, “Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effect on blood pressure and its use to identify and treat the renin factor,” Hypertension, vol. 2, no. 4, pp. 586–593, 1980. View at Google Scholar · View at Scopus
  10. M. A. Weber, H. Black, G. Bakris et al., “A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 374, no. 9699, pp. 1423–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Krum and S. D. Katz, “Effect of Endothelin-1 on exercise-induced vasodilation in normal subjects and in patients with heart failure,” American Journal of Cardiology, vol. 81, no. 3, pp. 355–358, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Cardillo, U. Campia, M. B. Bryant, and J. A. Panza, “Increased activity of endogenous endothelin in patients with type II diabetes mellitus,” Circulation, vol. 106, no. 14, pp. 1783–1787, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. K. J. Mather, B. Mirzamohammadi, A. Lteif, H. O. Steinberg, and A. D. Baron, “Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes,” Diabetes, vol. 51, no. 12, pp. 3517–3523, 2002. View at Google Scholar · View at Scopus
  14. C. Cardillo, U. Campia, M. Iantorno, and J. A. Panza, “Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients,” Hypertension, vol. 43, no. 1, pp. 36–40, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Lteif, P. Vaishnava, A. D. Baron, and K. J. Mather, “Endothelin limits insulin action in obese/insulin-resistant humans,” Diabetes, vol. 56, no. 3, pp. 728–734, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. J. G. Douglas, G. L. Bakris, M. Epstein et al., “Management of high blood pressure in African Americans: consensus statement of the hypertension in African Americans Working Group of the International Society on Hypertension in blacks,” Archives of Internal Medicine, vol. 163, no. 5, pp. 525–541, 2003. View at Publisher · View at Google Scholar
  17. F. Elijovich and C. L. Laffer, “Participation of renal and circulating endothelin in salt-sensitive essential hypertension,” Journal of Human Hypertension, vol. 16, no. 7, pp. 459–467, 2002. View at Publisher · View at Google Scholar · View at PubMed
  18. R. R. Wenzel, “Renal protection in hypertensive patients: selection of antihypertensive therapy,” Drugs, vol. 65, no. 2, pp. 29–39, 2005. View at Google Scholar
  19. H. H. Parving, F. Persson, J. B. Lewis, E. J. Lewis, and N. K. Hollenberg, “Aliskiren combined with losartan in type 2 diabetes and nephropathy,” New England Journal of Medicine, vol. 358, no. 23, pp. 2433–2446, 2008. View at Publisher · View at Google Scholar · View at PubMed
  20. R. M. Kedzierski and M. Yanagisawa, “Endothelin system: the double-edged sword in health and disease,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 851–876, 2001. View at Publisher · View at Google Scholar · View at PubMed
  21. S. B. Gurley and T. M. Coffman, “The renin-angiotensin system and diabetic nephropathy,” Seminars in Nephrology, vol. 27, no. 2, pp. 144–152, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. S. M. Wilhelm, M. S. Simonson, A. V. Robinson, N. T. Stowe, and J. A. Schulak, “Endothelin up-regulation and localization following renal ischemia and reperfusion,” Kidney International, vol. 55, no. 3, pp. 1011–1018, 1999. View at Publisher · View at Google Scholar · View at PubMed
  23. B. Hocher, C. Thöne-Reineke, P. Rohmeiss et al., “Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension,” Journal of Clinical Investigation, vol. 99, no. 6, pp. 1380–1389, 1997. View at Google Scholar
  24. M. S. Simonson and F. Ismail-Beigi, “Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop,” Journal of Biological Chemistry, vol. 286, no. 13, pp. 11003–11008, 2011. View at Publisher · View at Google Scholar · View at PubMed
  25. B. Hocher, A. Schwarz, D. Reinbacher et al., “Effects of endothelin receptor antagonists on the progression of diabetic nephropathy,” Nephron, vol. 87, no. 2, pp. 161–169, 2001. View at Publisher · View at Google Scholar
  26. M. Iglarz and E. L. Schiffrin, “Role of endothelin-1 in hypertension,” Current Hypertension Reports, vol. 5, no. 2, pp. 144–148, 2003. View at Google Scholar
  27. N. Dhaun, I. M. MacIntyre, D. Kerr et al., “Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease,” Hypertension, vol. 57, no. 4, pp. 772–779, 2011. View at Publisher · View at Google Scholar · View at PubMed
  28. L. V. D'Uscio, P. Moreau, S. Shaw, H. Takase, M. Barton, and T. F. Lüscher, “Effects of chronic ET(A)-receptor blockade in angiotensin II-induced hypertension,” Hypertension, vol. 29, no. 1, pp. 435–441, 1997. View at Google Scholar
  29. L. V. D'Uscio, S. Shaw, M. Barton, and T. F. Lüscher, “Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase role of blood pressure and endothelial function,” Hypertension, vol. 31, no. 6, pp. 1305–1310, 1998. View at Google Scholar
  30. T. Emori, Y. Hirata, K. Ohta et al., “Cellular mechanism of endothelin-1 release by angiotensin and vasopressin,” Hypertension, vol. 18, no. 2, pp. 165–170, 1991. View at Google Scholar
  31. A. Herizi, B. Jover, N. Bouriquet, and A. Mimran, “Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade,” Hypertension, vol. 31, no. 1 I, pp. 10–14, 1998. View at Google Scholar
  32. T. Imai, Y. Hirata, T. Emori, M. Yanagisawa, T. Masaki, and F. Marumo, “Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells,” Hypertension, vol. 19, no. 6, pp. 753–757, 1992. View at Google Scholar
  33. G. P. Rossi, A. Sacchetto, M. Cesari, and A. C. Pessina, “Interactions between endothelin-1 and the renin-angiotensin-aldosterone system,” Cardiovascular Research, vol. 43, no. 2, pp. 300–307, 1999. View at Publisher · View at Google Scholar
  34. H. Kawaguchi, H. Sawa, and H. Yasuda, “Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells,” Journal of Molecular and Cellular Cardiology, vol. 22, no. 8, pp. 839–842, 1990. View at Publisher · View at Google Scholar
  35. B. C. Berk, K. Fujiwara, and S. Lehoux, “ECM remodeling in hypertensive heart disease,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 568–575, 2007. View at Publisher · View at Google Scholar · View at PubMed
  36. J. Bohlender, S. Gerbaulet, J. Krämer, M. Gross, M. Kirchengast, and R. Dietz, “Synergistic effects of AT1 and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model,” Hypertension, vol. 35, no. 4, pp. 992–997, 2000. View at Google Scholar
  37. S. M. Gardiner, J. E. March, P. A. Kemp, J. J. Mullins, and T. Bennett, “Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats,” British Journal of Pharmacology, vol. 116, no. 4, pp. 2237–2244, 1995. View at Google Scholar
  38. T. Ikeda, H. Ohta, M. Okada et al., “Antihypertensive effects of a mixed endothelin-A- and -B-Receptor antagonist, J-104132, were augmented in the presence of an AT1—receptor antagonist, MK-954,” Journal of Cardiovascular Pharmacology, vol. 36, no. 5, pp. S337–S341, 2000. View at Publisher · View at Google Scholar
  39. D. E. Kohan, Y. Pritchett, M. Molitch et al., “Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 4, pp. 763–772, 2011. View at Publisher · View at Google Scholar · View at PubMed
  40. D. Joshi, R. Gupta, A. Dubey et al., “TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes,” Journal of Cardiovascular Pharmacology, vol. 54, no. 1, pp. 72–81, 2009. View at Publisher · View at Google Scholar · View at PubMed
  41. O. H. Cingolani, X. P. Yang, M. A. Cavasin, and O. A. Carretero, “Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats,” Hypertension, vol. 41, no. 2, pp. 249–254, 2003. View at Publisher · View at Google Scholar
  42. P. Pacher, L. Liaudet, P. Bai et al., “Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction,” Circulation, vol. 107, no. 6, pp. 896–904, 2003. View at Publisher · View at Google Scholar
  43. P. Pacher, J. G. Mabley, L. Liaudet et al., “Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure,” American Journal of Physiology, vol. 287, no. 5, pp. H2132–H2137, 2004. View at Publisher · View at Google Scholar · View at PubMed
  44. B. E. Westerhof, I. Guelen, N. Westerhof, J. M. Karemaker, and A. Avolio, “Quantification of wave reflection in the human aorta from pressure alone: a proof of principle,” Hypertension, vol. 48, no. 4, pp. 595–601, 2006. View at Publisher · View at Google Scholar · View at PubMed
  45. L. G. Luna, Histologic Staining Methods of the Armed Forces Institute of Pathology, Mcgraw-Hill, 3rd edition, 1998.
  46. S. P. Tofovic, H. Kusaka, C. K. Kost, and S. Bastacky, “Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF- hybrid rats,” Renal Failure, vol. 22, no. 4, pp. 387–406, 2000. View at Publisher · View at Google Scholar
  47. G. Grassi and E. L. Schiffrin, “Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions,” Journal of Hypertension, vol. 28, no. 9, pp. 1811–1813, 2010. View at Publisher · View at Google Scholar · View at PubMed
  48. S. Prabhakar, J. Starnes, S. Shi, B. Lonis, and R. Tran, “Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production,” Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2945–2952, 2007. View at Publisher · View at Google Scholar · View at PubMed
  49. R. E. Schmieder, A. U. Klingbeil, E. H. Fleischmann, R. Veelken, and C. Delles, “Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study,” Journal of the American Society of Nephrology, vol. 16, no. 10, pp. 3038–3045, 2005. View at Publisher · View at Google Scholar · View at PubMed
  50. M. Peppa-Patrikiou, M. Dracopoulou, and C. Dacou-Voutetakis, “Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors,” Metabolism, vol. 47, no. 11, pp. 1408–1412, 1998. View at Google Scholar
  51. V. Viswanathan, “Prevention of diabetic nephropathy: a diabetologist’s perspective,” Indian Journal of Nephrology, vol. 14, pp. 157–162, 2004. View at Google Scholar
  52. M. Y. Qi, H. R. Liu, D. Z. Dai, N. Li, and Y. Dai, “Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats,” Journal of Pharmacy and Pharmacology, vol. 60, no. 12, pp. 1687–1694, 2008. View at Publisher · View at Google Scholar · View at PubMed
  53. H. He, Q. Liu, M. Shi et al., “Cardioprotective effects of hydroxysafflor yellow a on diabetic cardiac insufficiency attributed to up-regulation of the expression of intracellular calcium handling proteins of sarcoplasmic reticulum in rats,” Phytotherapy Research, vol. 22, no. 8, pp. 1107–1114, 2008. View at Publisher · View at Google Scholar · View at PubMed
  54. M. Y. Qi, H. J. Xia, D. Z. Dai, and Y. Dai, “A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats,” Journal of Cardiovascular Pharmacology, vol. 47, no. 6, pp. 729–735, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. K. Amann, K. Münter, S. Wessels et al., “Endothelin a receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals,” Journal of the American Society of Nephrology, vol. 11, no. 9, pp. 1702–1711, 2000. View at Google Scholar
  56. E. Gagliardini, D. Corna, C. Zoja et al., “Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes,” American Journal of Physiology, vol. 297, no. 5, pp. F1448–F1456, 2009. View at Publisher · View at Google Scholar · View at PubMed
  57. D. Macconi, M. Ghilardi, M. E. Bonassi et al., “Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 477–489, 2000. View at Google Scholar
  58. P. Ruggenenti, L. Mosconi, and G. Vendramin, “ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome,” American Journal of Kidney Diseases, vol. 35, no. 3, pp. 381–391, 2000. View at Google Scholar
  59. A. Sorokin and D. E. Kohan, “Physiology and pathology of endothelin-1 in renal mesangium,” American Journal of Physiology, vol. 285, no. 4, pp. F579–F589, 2003. View at Google Scholar
  60. K. Amann, A. Simonaviciene, T. Medwedewa et al., “Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2572–2584, 2001. View at Google Scholar
  61. M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, and D. M. Pollock, “Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat,” Hypertension, vol. 56, no. 5, pp. 942–949, 2010. View at Publisher · View at Google Scholar · View at PubMed
  62. C. Zoja, X. H. Liu, M. Abbate et al., “Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin 1 gene in experimental membranous nephropathy,” Experimental Nephrology, vol. 6, no. 2, pp. 121–131, 1998. View at Google Scholar
  63. G. Remuzzi and T. Bertani, “Pathophysiology of progressive nephropathies,” New England Journal of Medicine, vol. 339, no. 20, pp. 1448–1456, 1998. View at Publisher · View at Google Scholar · View at PubMed
  64. I. Lehrke, R. Waldherr, E. Ritz et al., “Gene expression of the endothelin system in renal biopsies of proteinuric patients: effect of angiotensin converting enzyme,” Journal of the American Society of Nephrology, vol. 10, p. 80, 1999. View at Google Scholar
  65. R. G. Peterson, “The Zucker diabetic fatty rat,” in Animal Models of Diabetes: A Primer, A. F. S. Anders and S. Elazar, Eds., pp. 109–127, Harwood Academic, Amsterdam, The Netherlands, 2000. View at Google Scholar
  66. R. Dixon and N. J. Brunskill, “Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states,” Journal of the American Society of Nephrology, vol. 10, no. 7, pp. 1487–1497, 1999. View at Google Scholar
  67. R. J. Baines and N. J. Brunskill, “Tubular toxicity of proteinuria,” Nature Reviews Nephrology, vol. 7, no. 3, pp. 177–180, 2011. View at Publisher · View at Google Scholar · View at PubMed
  68. S. Yusuf, P. Sleight, J. Pogue et al., “Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients,” New England Journal of Medicine, vol. 342, no. 3, pp. 145–153, 2000. View at Publisher · View at Google Scholar
  69. D. Hileeto, M. Cukiernik, S. Mukherjee et al., “Contributions of endothelin-1 and sodium hydrogen exchanger-1 in the diabetic myocardium,” Diabetes/Metabolism Research and Reviews, vol. 18, no. 5, pp. 386–394, 2002. View at Publisher · View at Google Scholar · View at PubMed
  70. K. Witte, I. Reitenbach, K. Stolpe, L. Schilling, M. Kirchengast, and B. Lemmer, “Effects of the endothelin A receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats,” Journal of Cardiovascular Pharmacology, vol. 41, no. 6, pp. 890–896, 2003. View at Publisher · View at Google Scholar
  71. S. Verma, E. Arikawa, and J. H. McNeill, “Long-term endothelin receptor blockade improves cardiovascular function in diabetes,” American Journal of Hypertension, vol. 14, no. 7 I, pp. 679–687, 2001. View at Publisher · View at Google Scholar
  72. S. Dhein, S. Hochreuther, C. A. D. Spring, K. Bollig, C. Hufnagel, and M. Raschack, “Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model,” Journal of Pharmacology and Experimental Therapeutics, vol. 293, no. 2, pp. 351–359, 2000. View at Google Scholar
  73. B. Neal, S. MacMahon, and N. Chapman, “Blood pressure lowering treatment trialists collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood pressure- lowering drugs: results of prospectively designed overviews of randomized trials,” Lancet, vol. 356, no. 9246, pp. 1955–1964, 2000. View at Google Scholar